Literature DB >> 2401714

Testosterone and oxandrolone, a nonaromatizable androgen, specifically amplify the mass and rate of growth hormone (GH) secreted per burst without altering GH secretory burst duration or frequency or the GH half-life.

A Ulloa-Aguirre1, R M Blizzard, E Garcia-Rubi, A D Rogol, K Link, C M Christie, M L Johnson, J D Veldhuis.   

Abstract

We investigated the mechanisms by which androgens increase mean circulating GH concentrations in boys. We tested two hypotheses: 1) testosterone increases serum GH concentrations at least in part via an androgen receptor-mediated mechanism, rather than exclusively by way of aromatization to estrogen; 2) androgen augments one or more specific features to GH secretion (secretory burst number, amplitude, and/or duration) and/or prolongs the half-life of GH removal. To examine these hypotheses, prepubertal boys with constitutionally delayed development and/or growth were given injections of testosterone (100 mg monthly; n = 7) or treated with oral oxandrolone, a nonaromatizable androgen (1.25 mg twice daily; n = 5). Pulsatile GH release was studied before and during androgen administration by sampling blood at 20-min intervals for 24 h. The immunoreactive GH time series were subjected to a novel deconvolution technique, which revealed that 1) testosterone and oxandrolone each increased mean (24-h) serum GH concentrations significantly; 2) both androgens augmented the daily endogenous GH secretory rate significantly; 3) increased GH production resulted from a higher mass of GH secreted per burst and a higher maximal rate of GH secretion within each burst; and 4) androgens amplified the magnitude of the nyctohemeral rhythm in the mass (but not frequency) of GH secretory pulses. The observed effects of androgen were specific, since the number and duration of GH secretory bursts and the subject-specific GH half-life were unaltered by androgen treatment. We conclude that androgen acting apart from conversion to estrogen is capable of specifically activating the somatotropic axis via distinct neuroendocrine secretory mechanisms.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2401714     DOI: 10.1210/jcem-71-4-846

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  17 in total

Review 1.  Ageing, growth hormone and physical performance.

Authors:  F Lanfranco; L Gianotti; R Giordano; M Pellegrino; M Maccario; E Arvat
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 2.  Androgens and skeletal muscle: cellular and molecular action mechanisms underlying the anabolic actions.

Authors:  Vanessa Dubois; Michaël Laurent; Steven Boonen; Dirk Vanderschueren; Frank Claessens
Journal:  Cell Mol Life Sci       Date:  2011-11-19       Impact factor: 9.261

3.  The effect of short-term growth hormone or low-dose oxandrolone treatment in boys with constitutional growth delay.

Authors:  S Loche; C Pintor; P Cambiaso; A Lampis; D Carta; R Corda; M Cappa
Journal:  J Endocrinol Invest       Date:  1991-10       Impact factor: 4.256

Review 4.  Androgens and bone.

Authors:  D Vanderschueren; R Bouillon
Journal:  Calcif Tissue Int       Date:  1995-05       Impact factor: 4.333

5.  Effect of testosterone replacement therapy on the somatotrope responsiveness to GHRH alone or combined with pyridostigmine and on sympathoadrenal activity in patients with hypogonadism.

Authors:  G Del Rio; C Carani; A Velardo; G Zizzo; M Procopio; F Coletta; P Marrama; E Ghigo
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

6.  Pharmacodynamic effects of intravenous alcohol on hepatic and gonadal hormones: influence of age and sex.

Authors:  Vatsalya Vatsalya; Julnar E Issa; Daniel W Hommer; Vijay A Ramchandani
Journal:  Alcohol Clin Exp Res       Date:  2011-07-28       Impact factor: 3.455

7.  Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations.

Authors:  G Haeusler; H Frisch; K Schmitt; P Blümel; E Plöchl; M Zachmann; T Waldhör
Journal:  Eur J Pediatr       Date:  1995-06       Impact factor: 3.183

Review 8.  Androgen deficiency and aging in men.

Authors:  R S Swerdloff; C Wang
Journal:  West J Med       Date:  1993-11

9.  Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.

Authors:  Johannes D Veldhuis; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

10.  Influence of the high-affinity growth hormone (GH)-binding protein on plasma profiles of free and bound GH and on the apparent half-life of GH. Modeling analysis and clinical applications.

Authors:  J D Veldhuis; M L Johnson; L M Faunt; M Mercado; G Baumann
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.